OOIR: Observatory of International Research

Papers

(The median citation count of Pulmonary Pharmacology & Therapeutics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics	40
Echocardiographic effects of dupilumab in patients with severe type 2 asthma	38
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study	27
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	27
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies	24
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d	23
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients	20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function	20
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens	20
Editorial Board	18
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation	18
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential	17
Editorial Board	16
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets	15
Editorial Board	15
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis	14
Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment	14
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma	13
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study	13
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification	13
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea	12
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts	12
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury	12
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis	12
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis	12

Editorial Board	11
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials	11
Editorial Board	11
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler	11
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score	11
Ensifentrine approval: A milestone in the treatment of COPD	11
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant	11
Editorial Board	10
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients	10
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis	10
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?	10
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study	10
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics	10
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study	9
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling	9
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea	9
Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor	9
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease	9
Editorial Board	9
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats	8
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality	8
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients	8
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α	8
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway	8
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial	8
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany	7
β-sitosterol targets glucocorticoid receptor to reduce airway inflammation and remodeling in allergic asthma	7
The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis	7
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma	7
Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study	7
Tyvaso DPI: Drug-device characteristics and patient clinical considerations	7
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan	7
Repeated doses of captopril induce airway hyperresponsiveness by modulating the TRPV1 receptor in rats	7
Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma	7
The importance of biomarkers in the treatable-trait approach to chronic airway diseases	6
ALDH2 attenuates radiation-induced lung injury by inhibiting ROS and epithelial-mesenchymal transition mediated by the TGF-β1/Smad pathway	6
Advances in novel therapeutics for idiopathic pulmonary fibrosis	6
Icaritin protects against airway inflammation by inhibiting the TLR4/NF-κB pathway in vivo and in vitro	6
Editorial Board	6
Activating transcription factor 6 in the endothelial context	6
Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia	6
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a	6
Effect of daily dosing with tiotropium against methacholine induced bronchoconstriction in asthmatics	6
Artificial intelligence in the development of Rentosertib: A novel TNIK inhibitor for idiopathic pulmonary fibrosis – A letter to editor	6
Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract	6
Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities	6
Pulmonary drug delivery for acute respiratory distress syndrome	5
Corrigendum to “Bleomycin induced lung fibrosis increases work of breathing in the mouse” [Pulm. Pharmacol.Therapeut. 25 (2012) 281-285]	5
Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency	5
Dexmedetomidine reduces IL-4 and IgE expression through downregulation of theTLR4/NF-κB signaling pathway to alleviate airway hyperresponsiveness in OVA mice	5

Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway	5
Medication use in people with cystic fibrosis before and after modulator therapy	5
Targeted inhibition of IDO1 by Kushenol A enhances radiosensitivity in non-small cell lung cancer	5
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting	5
Targeting the immunometabolism interface: A novel strategy for IPF therapy	5
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression	5
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate	5
Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial	4
Demethyleneberberine alleviates Pseudomonas aeruginosa-induced acute pneumonia by inhibiting the AIM2 inflammasome and oxidative stress	4
Effect of roflumilast on airway remodeling in asthmatic mice exposed to or not exposed to cigarette smoke: Comparison with the effect of dexamethasone	4
Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures	4
Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis	4
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study	3
IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury	3
Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients	3
Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat	3
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance	3
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study	3
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers	3
Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3	3
The compound artemisinin-hydroxychloroquine ameliorates bleomycin-induced pulmonary fibrosis in rats by inhibiting TGF-β1/Smad2/3 signaling pathway	3
Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertensio	3
Statins’ still controversial role in pulmonary fibrosis: What does the evidence show?	3
Inhaled vs. intravenous vasodilators in perioperative pulmonary hypertension during chest surgery using cardiopulmonary bypass: A systematic review and meta-analysis	3
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation	3
Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study	3
Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis	3
A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells	3
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome	3